FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117222458> ?p ?o ?g. }

• W2117222458 endingPage "445" @default.
• W2117222458 startingPage "433" @default.
• W2117222458 abstract "// Shuang Yan 1 , Zhijie Li 1 and Carol J Thiele 1 1 Cell & Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute Correspondence: Carol J Thiele, email: // Keywords : neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, JAK inhibitor, STAT3 Received : March 13, 2013 Accepted : March 19, 2013 Published : March 19, 2013 Abstract The IL-6/JAK/STAT pathway is a key signal transduction pathway implicated in the pathogenesis of many human cancers, suggesting that kinase inhibitors targeting JAK/STAT3 may have a broad spectrum of antitumor activity. AZD1480, a pharmacological JAK1/2 inhibitor, exhibits anti-tumor potency in multiple adult malignancies. To evaluate the efficacy of inhibition of JAK/STAT3 signal transduction pathway we assessed the activity of AZD1480 in pediatric malignancies using preclinical models of three highly malignant pediatric solid tumors: neuroblastoma (NB), rhabdomyosarcoma (RMS) and the Ewing Sarcoma Family Tumors (ESFT). In this study, we employed panels of biomedical and biological experiments to evaluate the in vitro and in vivo activity of AZD1480 in NB, RMS and ESFT. Our data indicate that AZD1480 blocks endogenous as well as IL-6 induced STAT3 activation. AZD1480 decreases cell viability in 7/7NB, 7/7RMS and 2/2 ESFT cell lines (median EC 50 is 1.5 μM, ranging from 0.36-5.37μM). AZD1480 induces cell growth inhibition and caspase-dependent apoptosis in vitro and decreases expression of STAT3 target genes, including cell cycle regulators CyclinD1, 3 and CDC25A, anti-apoptotic genes Bcl-2 and survivin, the metastasis-related factor TIMP-1 and c-Myc. In vivo studies showed AZD1480 significantly decreased tumor growth and prolonged overall survival in tumor-bearing mice. Tumors from AZD1480-treated mice showed inhibition of activated STAT3 as well as decreased expression of STAT3 downstream targets. Our study provides strong evidence of the anti-tumor growth potency of JAK inhibitor AZD1480 in pediatric solid tumors, providing proof-of principle that inhibition of the JAK/STAT3 signal transduction could be a promising therapeutic target for high-risk pediatric solid tumors." @default.
• W2117222458 created "2016-06-24" @default.
• W2117222458 creator A5005300334 @default.
• W2117222458 creator A5019252943 @default.
• W2117222458 creator A5089979127 @default.
• W2117222458 date "2013-03-19" @default.
• W2117222458 modified "2023-10-03" @default.
• W2117222458 title "Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas<i>In vitro</i>and<i>In vivo</i>" @default.
• W2117222458 cites W1821858011 @default.
• W2117222458 cites W1982293120 @default.
• W2117222458 cites W1982334431 @default.
• W2117222458 cites W2000887760 @default.
• W2117222458 cites W2001472847 @default.
• W2117222458 cites W2003681585 @default.
• W2117222458 cites W2004695914 @default.
• W2117222458 cites W2009228236 @default.
• W2117222458 cites W2017201396 @default.
• W2117222458 cites W2017715430 @default.
• W2117222458 cites W2022897778 @default.
• W2117222458 cites W2030097185 @default.
• W2117222458 cites W2044227662 @default.
• W2117222458 cites W2047612670 @default.
• W2117222458 cites W2076752985 @default.
• W2117222458 cites W2083800105 @default.
• W2117222458 cites W2089614570 @default.
• W2117222458 cites W2089788088 @default.
• W2117222458 cites W2092765992 @default.
• W2117222458 cites W2096882042 @default.
• W2117222458 cites W2098640714 @default.
• W2117222458 cites W2100034382 @default.
• W2117222458 cites W2102128323 @default.
• W2117222458 cites W2105873215 @default.
• W2117222458 cites W2111336617 @default.
• W2117222458 cites W2127833800 @default.
• W2117222458 cites W2129763580 @default.
• W2117222458 cites W2130925781 @default.
• W2117222458 cites W2139383226 @default.
• W2117222458 cites W2160417212 @default.
• W2117222458 cites W2162617912 @default.
• W2117222458 cites W2327522594 @default.
• W2117222458 cites W2330829715 @default.
• W2117222458 doi "https://doi.org/10.18632/oncotarget.930" @default.
• W2117222458 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3717306" @default.
• W2117222458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23531921" @default.
• W2117222458 hasPublicationYear "2013" @default.
• W2117222458 type Work @default.
• W2117222458 sameAs 2117222458 @default.
• W2117222458 citedByCount "79" @default.
• W2117222458 countsByYear W21172224582013 @default.
• W2117222458 countsByYear W21172224582014 @default.
• W2117222458 countsByYear W21172224582015 @default.
• W2117222458 countsByYear W21172224582016 @default.
• W2117222458 countsByYear W21172224582017 @default.
• W2117222458 countsByYear W21172224582018 @default.
• W2117222458 countsByYear W21172224582019 @default.
• W2117222458 countsByYear W21172224582020 @default.
• W2117222458 countsByYear W21172224582021 @default.
• W2117222458 countsByYear W21172224582022 @default.
• W2117222458 countsByYear W21172224582023 @default.
• W2117222458 crossrefType "journal-article" @default.
• W2117222458 hasAuthorship W2117222458A5005300334 @default.
• W2117222458 hasAuthorship W2117222458A5019252943 @default.
• W2117222458 hasAuthorship W2117222458A5089979127 @default.
• W2117222458 hasBestOaLocation W21172224581 @default.
• W2117222458 hasConcept C112392421 @default.
• W2117222458 hasConcept C121608353 @default.
• W2117222458 hasConcept C126322002 @default.
• W2117222458 hasConcept C142724271 @default.
• W2117222458 hasConcept C150903083 @default.
• W2117222458 hasConcept C190283241 @default.
• W2117222458 hasConcept C207001950 @default.
• W2117222458 hasConcept C2775975398 @default.
• W2117222458 hasConcept C2776715637 @default.
• W2117222458 hasConcept C2778256501 @default.
• W2117222458 hasConcept C2778690821 @default.
• W2117222458 hasConcept C2778923194 @default.
• W2117222458 hasConcept C2780844630 @default.
• W2117222458 hasConcept C2993561819 @default.
• W2117222458 hasConcept C502942594 @default.
• W2117222458 hasConcept C54355233 @default.
• W2117222458 hasConcept C55493867 @default.
• W2117222458 hasConcept C62112901 @default.
• W2117222458 hasConcept C71924100 @default.
• W2117222458 hasConcept C81885089 @default.
• W2117222458 hasConcept C86803240 @default.
• W2117222458 hasConceptScore W2117222458C112392421 @default.
• W2117222458 hasConceptScore W2117222458C121608353 @default.
• W2117222458 hasConceptScore W2117222458C126322002 @default.
• W2117222458 hasConceptScore W2117222458C142724271 @default.
• W2117222458 hasConceptScore W2117222458C150903083 @default.
• W2117222458 hasConceptScore W2117222458C190283241 @default.
• W2117222458 hasConceptScore W2117222458C207001950 @default.
• W2117222458 hasConceptScore W2117222458C2775975398 @default.
• W2117222458 hasConceptScore W2117222458C2776715637 @default.
• W2117222458 hasConceptScore W2117222458C2778256501 @default.
• W2117222458 hasConceptScore W2117222458C2778690821 @default.
• W2117222458 hasConceptScore W2117222458C2778923194 @default.
• W2117222458 hasConceptScore W2117222458C2780844630 @default.

• next